Journal
CURRENT DIABETES REPORTS
Volume 13, Issue 3, Pages 307-318Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-013-0377-9
Keywords
GLP-1; DPP-4; GLP-1 receptor agonists; DPP-4 inhibitors; Incretin; Type 2 diabetes; Weight loss; Hypoglycemia; Cardiovascular risk factors
Categories
Funding
- NIH grant [DK083554]
Ask authors/readers for more resources
Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available